Soluble VE-cadherin disrupts endothelial barrier function via VE-PTP/RhoA signalling

We generated recombinant human sVE-cadherin (extracellular domains EC1-5) which was applied to human dermal microvascular endothelial cells (HDMEC) to investigate it`s role in endothelial barrier function. In other experiments we observed that sVE-cadherin disrupted endothelial barrier function by dismantling the VE-cadherin complex at cell borders via VE-PTP-dependent RhoA activation. The sequencing project compares untreated HDMEC vs treated cells. Overall design: Comparative gene expression profiling analysis of Soluble VE-cadherin treated and control human primary endothelial (HDMEC) cells